Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- BULLETIN
September 20, 2004
- MONITOR
September 20, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
September 20, 2004
- DIAGNOSTIC NEWS IN BRIEF
September 20, 2004
- MEDICAL DEVICE NEWS IN BRIEF
September 13, 2004
- REGULATORY NEWS IN BRIEF
September 13, 2004
- Semi-annual Business Results
September 13, 2004
- Importance of New Safety Measures Stressed: Mr Asonuma of PFSB
September 13, 2004
- DIAGNOSTIC NEWS IN BRIEF
September 13, 2004
- Precautions against Interstitial Pneumonia Required for 220 Active Ingredients: PFSB
September 13, 2004
- OTC NEWS IN BRIEF
September 13, 2004
- Korosho to Further Promote Mutual GMP Recognition of Drugs
September 13, 2004
- PRESS SEMINAR
September 13, 2004
- Specialized Pharmacists Needed in Specific Fields: Mr Ishii
September 13, 2004
- Results of PII Trial of CS-747 Announced at ESC 2004: Sankyo
September 13, 2004
- Monkasho to Request 13% Increase in FY2005 Budget
September 13, 2004
- CHARM Study Reconfirms Efficacy of Candesartan in CHF: Takeda
September 13, 2004
- HPB Seeks 41.3% Increase in Spending on Medical Safety Measures in FY2005
September 13, 2004
- NEW PRODUCTS
September 13, 2004
- Japanese Gov't Should Strengthen Infrastructure of the Pharm Industry: Mr Taurel of Eli Lilly
September 13, 2004
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…